spot_img
Thursday, November 19, 2026

Coriell Institute expands Camden research footprint with two new labs in cancer immunotherapy and epigenetics

The Coriell Institute for Medical Research has recruited two biomedical researchers—Huda Salman and Rexxi Prasasya—to establish new laboratories in Camden focused on next-generation cancer immunotherapy, epigenetics, and reproductive biology.

The appointments mark the latest step in Coriell’s effort to build out its translational research capabilities alongside regional healthcare partners.

“Attracting scientists of this caliber is central to Coriell’s future,” Jean-Pierre Issa, president and CEO of Coriell, said. “Huda and Rexxi bring complementary expertise, and with our partners at Cooper Norcross Health, we are building a research community in Camden that can compete nationally. We are proud to have them on our team.”

Salman joins Coriell with a background in hematologic malignancies and cellular immunotherapy. Her new laboratory will focus on developing next-generation chimeric antigen receptor (CAR) T-cell therapies—a treatment approach that engineers a patient’s own immune cells to recognize and attack cancer cells.

Working in partnership with Cooper Norcross Health through the Camden Cancer Research Center (CCRC), Salman’s team aims to translate laboratory findings directly into clinical applications for difficult-to-treat blood cancers.

“Coriell offers a rare combination of scientific rigor, collaborative spirit, and a close connection to the community it serves,” Salman said. “I’m excited to establish my laboratory here and to advance next-generation CAR T-cell therapies for hard-to-treat blood cancers. Working with our partners at Cooper Norcross Health through the CCRC, we can move more directly from the laboratory bench toward the clinic, with the goal of bringing new options to patients.”

Prior to joining Coriell, Salman served as the inaugural executive director of the Brown Center for Immunotherapy at Indiana University School of Medicine. She also previously held leadership roles at Stony Brook University, including section chief of hematological malignancies and director of the CAR T-cell program, where she developed a first-in-human CD4-directed CAR T-cell therapy program targeting T-cell cancers. She earned her medical and doctoral degrees from the University of Jordan and completed clinical and research training in New York.

Prasasya brings expertise in developmental biology and epigenetics—the study of chemical modifications that regulate gene activity without altering the underlying DNA sequence. At Coriell, her laboratory will investigate how DNA methylation patterns are established during reproductive cell development, how disruptions to those mechanisms contribute to cancer and other diseases, and how epigenetic insights can advance understanding of fertility and women’s reproductive health.

“Some of the most important questions in biology come down to how a cell knows which genes to switch on, and how that memory is set in the first place,” Prasasya said. “At Coriell, I have the freedom and the resources to pursue those questions in reproductive cells, where the stakes for fertility and for diseases like cancer are so high.”

Prasasya previously conducted research at the University of Pennsylvania’s Perelman School of Medicine, studying epigenetic regulation and genomic imprinting—including identifying an unexpected role for the TET1 enzyme in directing DNA methylation in reproductive cells. She holds degrees from the University of Wisconsin–Madison and Northwestern University.

Founded 73 years ago, Camden-based Coriell conducts research across cancer, aging, epigenomics, stem cells, and personalized medicine, while operating major international biobanks for five National Institutes of Health (NIH) institutes.

+ posts

Get the Latest News

Sign up to get all the latest news, offers and special announcements.

Get our Print Edition

All the latest updates, delivered.

Latest Posts

Get the Latest News

Sign up to get all the latest news, offers and special announcements.

Get our Print Edition

All the latest updates, delivered.